Company ProfilePremium

Atul Ltd.

Company Profile Analysis

Tickers: ATUL.NS, 500027.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Atul Ltd. - Chemicals & Materials showcase

Year Founded & Workforce

1947

3,139 Employees

Industry

Chemicals & Materials

Services

Bisphenol A-based unmodified liquid resinBisphenol A-based modified liquid resinBisphenol A-based solid resinBisphenol F-based resinBisphenol A/F-based resin
Atul Ltd. logo

Atul Ltd. Employee Contacts

4 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Atul Ltd. Overview

Atul Ltd is one of India's oldest and most diversified integrated chemical companies, founded in 1947 by Kasturbhai Lalbhai and still promoter-led as part of the Lalbhai Group. From a 1,300-acre flagship complex in Valsad district, Gujarat, and seven other production sites, it makes about 900 products and 400 formulations under 142 brands for some 4,000 customers in 88 countries across 32 industries (AM26). Its portfolio runs from chlor-alkali and bulk intermediates through epoxy resins, textile dyes, aromatics, crop protection actives, active pharmaceutical ingredients and retail adhesives. It reports two segments, Life Science Chemicals and Performance and Other Chemicals. FY2026 consolidated revenue was ₹6,274 crore with profit after tax of ₹689 crore, and the group ended the year with ₹1,578 crore of treasury funds net of borrowings. The investment case rests on monetising a completed capex cycle, backward integration, and a net-cash balance sheet, offset by commodity exposure and modest returns on capital.

A note on identifiers. One secondary source (Equitybulls, July 2026) printed the BSE code as 531000. This conflicts with the BSE scrip code 500027 shown by Screener and by the company's own Regulation 30 filing coverage, and is treated here as an error in that source.


The company's own description. Atul describes itself as "an integrated chemical company with robust in-house infrastructure and a comprehensive product portfolio serving diverse industrial sectors worldwide" (AM26). The FY2025 integrated report characterises it as one of the largest integrated chemical companies in India, a diversified enterprise and part of the Lalbhai Group, catering to the needs of various industries (IAR25). The profile disclosed at the April 2026 analyst meet is: 8 production sites, 142 brands, a 73 MW captive power plant, 32 industries served, 32 MLD of effluent treatment capacity, about 4,000 customers, roughly 900 products and 400 formulations, and sales into 88 countries (AM26).

Independent characterisation. Atul is best understood as a chemistry conglomerate assembled over seven decades around a single very large integrated site. It is not a pure specialty chemical company. Its economics combine three distinct types of business. The first is commodity and near-commodity production, including caustic soda and chlorine, sulphuric acid, liquid epoxy resin, and sulphur black dyes, where margins track input spreads and Chinese supply. The second is a set of niche global positions in intermediates and actives, such as para-cresol and its derivatives, resorcinol, 1,3-cyclohexanedione, dapsone, sulfones, 2,4-D and indoxacarb, where Atul has scale and process know-how. The third is a small but growing branded retail layer, comprising crop protection brands sold to Indian farmers and the Lapox, Polygrip and Lacare adhesives and care brands sold through distributors.

Business model. The model is manufacturing-led and vertically integrated. Atul produces its own chlorine, caustic, sulphuric acid, phosgene, monochloroacetic acid (through the Anaven joint operation with Nouryon) and several key intermediates, and consumes a meaningful share of these captively. Inter-segment and intra-group transfers are therefore large: FY2026 segment revenue including inter-segment transfers was ₹1,805 crore for Life Science Chemicals and ₹4,609 crore for Performance and Other Chemicals, against consolidated revenue of ₹6,274 crore (AM26). The July 2026 decision to build MCPP-p and MCPA capacity is a textbook example of the model: both herbicides are derived from o-cresol and monochloroacetic acid, which the group already makes (Business Upturn, 24 July 2026).

Revenue model. Revenue is overwhelmingly from the sale of manufactured goods. There is no subscription or licensing stream of any significance. A small "Others" segment includes agribiotech (tissue-cultured date palms), food products and services; it contributed ₹25.98 crore in Q1 FY2027 (Q1FY27). The split between business-to-business and retail sales is not disclosed in a single figure, but the two explicitly retail sub-segments are small: Crop Protection – Retail recorded ₹278 crore in FY2026, and Polymers – Retail is not separately quantified in the slides retrieved (AM26).

Value chain position. Atul sits in the middle of the chemical value chain. It buys petrochemical and inorganic feedstocks (phenol, toluene, epichlorohydrin and bisphenol-A inputs, salt, sulphur, benzene derivatives), converts them through multi-step synthesis, and sells intermediates, actives, resins, dyes and formulations to formulators, compounders, textile processors, agrochemical majors, pharmaceutical companies, tyre makers, paint companies, wind-blade makers and, at the retail end, to farmers and tradespeople.

Customer types and end-markets. The company lists the following industries served: adhesives, aerospace and defence, agriculture, automobile, composites, construction, cosmetics, dyestuff, electrical and electronics, flavour and fragrance, foam and furnishing, food and beverage, footwear, foundry, furniture, glass, handicraft, home care, horticulture, health care, marine, paint and coatings, paper, personal care, pharmaceuticals, rubber, soap and detergent, sport and leisure, stone care, textile, tyre and wind energy (AM26).

Geographic model. India is the larger market and is growing faster. In FY2026, revenue in India grew 14% (12% volume, 2% price) and revenue outside India grew 7% (5% volume, 2% price) (AM26). Overseas subsidiaries in the USA, Europe, China, Brazil, the Middle East and Ireland exist, in the company's words, "to work closely with customers" (AM26).

Strategy

Stated strategy. At the April 2026 analyst meet, under the theme "Rooted | Responsible | Rising", management set out "five enduring mandates" for "securing the future" (AM26):

  1. Achieve excellence in R&D, technology and manufacturing.

  2. Pervade technology (AI and others) across all functions.

  3. Become world-class in people productivity and remain lean on fixed cost.

  4. Conserve cash, measuring performance by free cash flow.

  5. Work closely with consumers and customers to identify big ideas, but start small.

Growth themes. For B2B, growth is to come through existing, downstream and upstream products, related products, new product groups and new businesses. For B2C, through existing products, related products, new product groups and new businesses. The stated routes are to "build, form joint ventures, acquire" (AM26).

Medium-term targets. Atul does not publish numeric guidance. Its long-range slide plots revenue of ₹1,044 crore (FY2008), ₹2,043 crore (FY2013), ₹3,338 crore (FY2018) and ₹5,428 crore (FY2023), each a 63–96% increase over five years, and leaves FY2028 as a question mark with the caption that the best way to predict the future is to create it. A continuation of the historical pattern would imply FY2028 revenue in the region of ₹8,800–9,000 crore; that is an inference from the chart, not management guidance.

Latent capacity. The central operating message is that growth for the next two to three years requires little new capital. Management quantified sales yet to be realised at ₹600 crore from new projects and ₹1,100 crore from existing capacity (AM26). Sub-segment disclosure of unrealised sales potential totals: Polymers – Performance Materials ₹650 crore, Colors ₹310 crore, Aromatics ₹212 crore, Anaven ₹137 crore, Atul Bioscience ₹110 crore, Bulk Chemicals and Intermediates ₹83 crore, Crop Protection – Bulk Actives ₹80 crore, Pharmaceuticals ₹65 crore and Floras ₹54 crore, which sum to ₹1,701 crore (AM26). A year earlier, management had cited more than ₹2,500 crore of unrealised potential, of which about ₹1,700 crore from recently concluded capex and ₹800 crore from unutilised capacity (Trendlyne summary of broker note, 2025). One broker cites ₹1,800–2,000 crore after Q1 FY2027 (HDFC Sky).

Initiatives announced or completed in the last 24 months

Products & Services

Product counts, customer counts, market-share descriptors and competitor counts below are from AM26 and refer to FY2026. Atul discloses market share numerically only for selected products; elsewhere it uses "significant" or "insignificant", qualified as global (G) or India (I). Pricing models are not disclosed for any product line; sales are understood to be on negotiated contract and spot terms for B2B products and list-price-less-scheme terms through distributors for retail products.

Life Science Chemicals

ProductDescriptionPosition disclosed
2,4-D (acid, salts, esters)Phenoxy herbicide for broadleaf weed control; Atul was the first Indian producer of 2,4-D acid13% global share; competitors in Australia (1), Asia (8), Europe (1), North America (1), South America (1)
IndoxacarbOxadiazine insecticide14% global share; six Asian competitors
Sulfonylurea herbicidesLow-dose herbicide familyNamed as a key product group (SCR citing AR26); share not disclosed
MCPP-p (mecoprop-p) and MCPAPhenoxy herbicides; new greenfield units of 1,000 TPA and 750 TPA approved July 2026, completion targeted in 67 weeksNo existing capacity; ₹167 crore investment excluding working capital and GST
Other herbicides, insecticides, fungicidesBalance of the 36-product rangeNot itemised in sources retrieved
BrandCategoryMarket share (FY2026)
ZuraHerbicide brand29%
SalixHerbicide brand (2,4-D based)28%
CynoBrand in its category32%
SindicaBrand in its category13%
AmsacBrand in its category11%
Rymix, Rhyzo, LoxoNamed best-selling brandsShare not disclosed
Mylonis (launched May 2026)Patented fungicide combining azoxystrobin, isoprothiolane and mancozeb for rice sheath blight, blast and grain discolourationNew
Salix Gold (launched May 2026)2,4-D sodium salt water-dispersible granule for post-emergence control of broadleaf weeds and sedges in riceNew
Tikadis (launched May 2026)Patented seed treatment combining azoxystrobin, carbendazim and thiamethoxam for groundnut and soybeanNew
ProductDescriptionPosition disclosed
DapsoneAnti-infective API; USFDA-approved facility since 2015Significant global share; competitors in India and Europe
1-CEICPhosgene-derived intermediateSignificant India share; competition from China
Phosgene chemicalsChloroformates, isocyanates and carbamates familyInsignificant global share; two producers in North America and Europe are expected to exit, which Atul flags as a share opportunity
APIs and intermediates (Atul Bioscience)Therapeutic areas include antiasthmatic, antidepressant, antidiabetic, antifungal, anti-infective, anti-inflammatory, antineoplastic, antiretroviral and cardiovascular; also contract manufacturing11 DMFs filed in FY2026

Crop Protection – Bulk Actives (36 products, 224 customers; serves agriculture and public health; addressable market cited as US$77 billion for crop protection and US$1 billion for public health)

FY2026 sub-segment sales grew 16% in value and 10% in volume; two new products were launched and five developed for FY2027 launch (AM26). FY2025 sales were ₹627 crore, up 28% from ₹491 crore (FY2025 MD&A via IIFL).

Crop Protection – Retail (71 formulations under 59 brands, 2,099 customers; India agriculture market cited at ₹12,000 crore growing 7%)

Market shares are within each product's own category in India as defined by Atul. Sales were ₹195 crore (FY2023), ₹203 crore (FY2024), ₹253 crore (FY2025) and ₹278 crore (FY2026). In FY2026 the business secured registrations for three in-house developed products, launched four products including one biological, and entered eastern Maharashtra (AM26; NewsVoir release, May 2026).

Pharmaceuticals (90 products, 300 customers; addressable markets cited at ₹7,000 crore for pharmaceuticals and ₹1,000 crore for specialty chemicals)

Floras (2 products, 242 customers): tissue-cultured date palm plantlets through Atul Rajasthan Date Palms and DPD Ltd, with a significant global share against 32 competitors across Asia, Africa, Europe, North America and India. FY2026 sales rose 16% in value and 18% in volume, and in-vitro plantlets were exported (AM26).

Performance and Other Chemicals

ProductDescriptionPosition disclosed
p-CresolCore aromatic intermediate; Atul was first to make it in IndiaSignificant global share; four Asian competitors
p-Cresol derivatives (p-Cd)Downstream antioxidants and intermediatesSignificant global share
p-Anisic aldehydeFragrance and UV-filter intermediate (tagged LSC)Significant global share
p-Anisyl alcoholFragrance ingredient (tagged LSC)Significant India share
ProductDescriptionPosition disclosed
ResorcinolUsed in tyre adhesion, UV stabilisers and resinsSignificant India share; three Asian competitors
Resorcinol-formaldehyde resinsTyre and rubber adhesion promotersSignificant India share
1,3-CyclohexanedioneHerbicide intermediateSignificant global share
Caustic soda and chlorineChlor-alkali, largely via Atul Products LtdSignificant in South Gujarat and Maharashtra
Sulphuric acidIncluding via Amal LtdSignificant in South Gujarat
Monochloroacetic acidVia Anaven LLP with NouryonShare not disclosed
ProductDescriptionPosition disclosed
Epoxy resins and curing agentsLiquid epoxy resin (50 KT plant), specialty epoxies and hardeners for coatings, construction, electrical, composites, adhesives and aerospaceSignificant India share; competitors in India (3), Asia (8), Europe and USA (6)
Reactive diluentsViscosity modifiers for epoxy systemsSignificant India share
SulfonesIncluding DDS used as a high-performance curing agentSignificant global share
BrandCategoryIndia market share (FY2026)
LapoxEpoxy adhesives and construction chemicals7%
PolygripRubber-based and synthetic adhesives for footwear, furniture and foam6%
LacareCare products1%

Aromatics (37 products, 405 customers; end-uses in additives, fragrance and personal care)

FY2026 sales fell 6% in value and 7% in volume. Three new products were commercialised and hybrid power use rose from 36% to 55% (AM26).

Bulk Chemicals and Intermediates (23 products, 249 customers)

FY2026 sales rose 5% in value with volume down 1% (AM26).

Colors (525 products, 345 customers): vat dyes (significant India and global share against 13 Indian and 30 overseas competitors), sulphur black (significant in India, insignificant globally), other textile dyes including reactive and disperse (insignificant share in a field of about 210 Indian and 400 overseas competitors), and high-performance pigments (insignificant global share). Eleven new liquid sulphur colour products were launched in FY2026; sales rose 9% in value and 5% in volume. Rudolf Atul Chemicals adds textile auxiliaries and introduced 27 new products in FY2026, contributing 11% of its sales (AM26).

Polymers – Performance Materials (49 products, 202 formulations, 511 customers)

This is the group's largest business: sales of ₹1,268 crore (FY2023), ₹1,194 crore (FY2024), ₹1,446 crore (FY2025) and ₹1,710 crore (FY2026), with international sales at 45%, 40%, 40% and 38% respectively. FY2026 growth was 18% in value and 21% in volume (AM26).

Polymers – Retail (82 products, 618 customers)

FY2026 sales grew 20% in value and 19% in volume. A distributor loyalty programme and construction and PVA adhesives lines were introduced (AM26).

Financial Narrative

All figures consolidated, ₹ crore. FY2022–FY2026 income statement, balance sheet and cash flow lines are from SCR unless stated; FY2025–FY2026 company-reported figures are from AM26. Indian Accounting Standards do not require a gross profit line and Atul does not report one, so gross profit and gross margin are not publicly disclosed.

Income statement

Notes: EBITDA for FY2024–FY2026 is as reported by the company (IAR24; AM26); FY2022–FY2023 EBITDA and all EBIT figures are derived as operating profit plus other income, less depreciation. Other income for FY2025–FY2026 per the company is ₹109 crore and ₹203 crore, slightly different from SCR's classification. Diluted EPS is not separately verified; Atul has no known dilutive instruments, so diluted EPS is expected to equal basic. Dividend per share is derived from the dividend percentages on a ₹10 face value disclosed in AM26 (250%, 325%, 200%, 250%, 300%); FY2023 includes a one-time 75% special dividend, and the FY2026 dividend was proposed in April 2026 for approval at the 31 July 2026 AGM.

Margins and growth

Derived. Revenue CAGR FY2022–FY2026 (four years) is 5.4%; FY2021–FY2026 (five years, from ₹3,731 crore) is 11.0%, matching SCR's five-year compounded sales growth.

Balance sheet (as at 31 March)

Sources: SCR; treasury funds from AM26. The company's own presentation shows total assets of ₹7,001 crore (FY2025) and ₹7,900 crore (FY2026) and total equity including non-controlling interests of ₹5,662 crore and ₹6,296 crore; the differences from SCR reflect classification and the treatment of minority interest. Net debt is negative in every year, so the group is in a net cash position equal to the treasury funds line. CARE noted that on a standalone basis Atul had only cash credit limits on its books at 31 March 2025, so group borrowings sit mainly in subsidiaries (CARE, 1 October 2025).

Working capital (company basis, excluding liquid investments)

Source: AM26. Management states net working capital improved by 10 days in FY2026.

Cash flow

Sources: SCR; capex trend from AM26, which notes that expenditure differs from the amount capitalised. Cash-flow-statement capex was ₹246 crore in FY2025 and ₹172 crore in FY2026; dividends paid were ₹59 crore and ₹74 crore (AM26).

Ratios

ROE, ROA, debt to equity, interest coverage and asset turnover are derived from the tables above using average balances; ROCE and the working capital days are from SCR. Net debt to EBITDA is negative throughout (net cash). The company's own RoCE figures differ by definition: 23.6% (FY2022), 19.2% (FY2023) and 12.5% (FY2024) in IAR25, while AM26 reports 15% for FY2025 and 17% for FY2026 on average capital employed of ₹4,872 crore and ₹5,525 crore; IAR25 shows 13.7% for FY2025. The two FY2025 figures conflict and likely reflect standalone versus consolidated bases. The current ratio was 2.96x at 31 March 2025 (CARE); on the AM26 balance sheet it is 3.3x for FY2025 and 3.6x for FY2026 (derived, consolidated).

Quarterly progression

Source: SCR.

Commentary on trends and drivers.

Revenue: FY2022 was a post-pandemic price peak, FY2023 held on prices, and FY2024 saw a 13% fall as realisations dropped about 19% while volumes rose about 5% on a standalone basis (IAR24). Recovery since has been volume-led: FY2026 revenue grew 12%, of which roughly 10 points were volume and about 8 points came from recently completed projects (AM26).

Margins: Operating margin before other income fell from 25% in FY2021 to 13.5% in FY2024 and has recovered only to 16.5%. Depreciation nearly doubled from ₹177 crore to ₹322 crore as the capex cycle was capitalised, which is why EBIT margin (14.5%) remains below FY2022 (16.1%) despite higher revenue. Q1 FY2027's 21% operating margin is the first quarter back above 20% since FY2021; one broker attributed it partly to better pricing and inventory gains (HDFC Sky, August 2026), so its durability is unproven.

Other income: Other income doubled to about ₹203–206 crore in FY2026 and accounted for roughly 23% of PBT. It included an income tax refund of ₹47 crore from old assessments, and a subsidiary received ₹15 crore of interest assistance (AM26). Underlying earnings growth is therefore lower than the 38% reported PAT growth.

Cash flow: Operating cash flow of ₹1,023 crore in FY2026 was the highest in the company's history and capex of ₹175 crore the lowest in eleven years, producing free cash flow of about ₹851 crore. Almost all of it (₹768 crore) was placed in treasury funds, and dividends took ₹74 crore.

Returns: ROE of 11.7% is well below the 10-year average of 13% (SCR) and roughly half the FY2020–FY2021 level. A cash and investment pile approaching one-third of total assets weighs on headline returns.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentSub-segments (businesses)Principal product groups

Life Science Chemicals

Crop Protection – Bulk Actives; Crop Protection – Retail; Pharmaceuticals; Aromatics (part: p-anisic aldehyde and p-anisyl alcohol chains are tagged LSC); Floras (shown under LSC in AM26)

Herbicides, insecticides, fungicides, APIs and API intermediates, phosgene derivatives, tissue-cultured date palms

Performance and Other Chemicals

Aromatics (p-cresol chain); Bulk Chemicals and Intermediates; Colors; Polymers – Performance Materials; Polymers – Retail

Para-cresol derivatives, resorcinol, caustic soda, chlorine, sulphuric acid, textile dyes, pigments, epoxy resins and curing agents, sulfones, adhesives

Others

Agribiotech, food products, services

Small; ₹25.98 crore revenue in Q1 FY2027 (Q1FY27)

Revenue by Segment

SegmentFY2022FY2023FY2024FY2025FY2026

Life Science Chemicals revenue (INR Cr)

1,4651,9591,4271,6921,805

Performance and Other Chemicals revenue (INR Cr)

3,7593,7063,4534,0584,609

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%)

SegmentFY2023FY2024FY2025FY2026

Life Science Chemicals YoY growth (%)

33.7-27.218.66.7

Performance and Other Chemicals YoY growth (%)

-1.4-6.817.513.6

Revenue by Segment (%)

SegmentFY2022FY2023FY2024FY2025FY2026

Life Science Chemicals share (%)

28.034.629.229.428.1

Performance and Other Chemicals share (%)

72.065.470.870.671.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2025FY2026

Life Science Chemicals EBIT (INR Cr)

347417

Life Science Chemicals EBIT margin (%)

2023

Life Science Chemicals net capital employed (INR Cr)

1,0391,074

Life Science Chemicals RoCE (%)

3339

Performance and Other Chemicals EBIT (INR Cr)

345417

Performance and Other Chemicals EBIT margin (%)

89

Performance and Other Chemicals net capital employed (INR Cr)

2,9142,936

Performance and Other Chemicals RoCE (%)

1214

Group Entities

EntityAtul holdingActivityFY2026 note

Atul Bioscience Ltd

100%

APIs and intermediates; plants at Atul and Ambernath

Sales value up 9%; 11 DMFs filed in FY2026 (7 in FY2025); both units USFDA inspected

Atul Products Ltd

100%

Caustic soda and chlorine complex

Sales ₹504 crore (FY2025 ₹352 crore; FY2024 ₹65 crore, a partial year)

Amal Ltd (consolidated)

49.86%

Sulphuric acid and derivatives

Sales ₹240 crore (FY2025 ₹135 crore; FY2024 ₹86 crore; FY2023 ₹61 crore)

Rudolf Atul Chemicals Ltd

50% JV with Rudolf GmbH

Textile chemicals

Sales ₹161 crore (FY2025 ₹165 crore; FY2024 ₹138 crore; FY2023 ₹110 crore)

Anaven LLP

50:50 joint operation with Nouryon

Monochloroacetic acid

Sales value down 4%, volume down 2%

DPD Ltd, UK

98%

Date palm tissue culture

Phase-2 expansion inaugurated June 2025

Atul Rajasthan Date Palms Ltd

—

Tissue-cultured date palms

ERP implemented; ramp-up under way

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

5,0815,4284,7265,5836,274

Operating profit before other income (INR Cr)

9138076399181,034

Other income (INR Cr)

828665115206

EBITDA including other income (INR Cr)

9958937051,0221,234

Depreciation (INR Cr)

177198243317322

Operating income, EBIT (INR Cr)

818695462705912

Interest (INR Cr)

98112417

Profit before tax (INR Cr)

810688451692901

Net profit after tax (INR Cr)

605507324499689

Basic EPS (INR)

204.23174.19109.71164.37230.25

Dividend per share (INR)

2532.5202530

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

36.26.8-12.918.112.4

Operating margin before other income (%)

18.014.913.516.416.5

EBITDA margin including other income (%)

19.616.514.918.319.7

EBIT margin (%)

16.112.89.812.614.5

Net margin (%)

11.99.36.98.911.0

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

5,6905,7526,4556,9807,870

Shareholders' equity, capital plus reserves (INR Cr)

4,4294,6725,1145,5986,221

Total borrowings (INR Cr)

14452237202183

Fixed assets, net (INR Cr)

1,6341,7702,7922,8472,676

Capital work in progress (INR Cr)

4201,033281124110

Investments (INR Cr)

1,3398811,3921,7662,592

Treasury funds net of borrowings (INR Cr)

5943073616911,578

Liquidity & Coverage Ratios

MetricFY2025FY2026

Inventories (INR Cr)

765859

Trade receivables (INR Cr)

1,1261,271

Other current assets (INR Cr)

237278

Current liabilities (INR Cr)

8061,068

Net working capital (INR Cr)

1,3221,340

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operating activities (INR Cr)

2317076676031,023

Cash from investing activities (INR Cr)

-163-469-683-494-891

Cash from financing activities (INR Cr)

-57-25738-118-98

Capital expenditure, company trend basis (INR Cr)

591874504270175

Free cash flow, SCR basis (INR Cr)

-359-167164334851

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Return on equity (%)

14.711.16.69.311.7

Return on assets (%)

11.48.95.37.49.3

Return on capital employed, SCR basis (%)

191591315

Debt to equity (x)

0.030.010.050.040.03

Interest coverage, EBIT to interest (x)

9187422954

Asset turnover (x)

0.960.950.770.830.84

Debtor days

7157727474

Inventory days

122101909790

Payable days

9069848294

Cash conversion cycle (days)

10389778970

Income Statement and Margin Analysis (%)

MetricQ1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027

Revenue (INR Cr)

1,4781,5521,5741,6701,848

Operating profit (INR Cr)

236267247281394

Operating margin (%)

1617161721

Profit before tax (INR Cr)

177231203289347

Net profit (INR Cr)

132182164211254

EPS (INR)

43.4060.8854.6071.3883.32

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

India (INR Cr)

1,9642,5262,8682,7123,328

Outside India (INR Cr)

1,7672,5552,5602,0142,255

Region Margins & Growth (%) and Revenue by Region (%)

MetricFY2022FY2023FY2024FY2025

India growth YoY (%)

28.613.5-5.422.7

Outside India growth YoY (%)

44.60.2-21.312.0

India share of revenue (%)

49.752.857.459.6

Outside India share of revenue (%)

50.347.242.640.4

Revenue by Region (FY2023–FY2024)

MetricFY2023FY2024

Life Science Chemicals domestic (INR Cr)

631.82701.82

Life Science Chemicals export (INR Cr)

844.85555.47

Capital Markets

ItemValueSource

Share price

₹5,861

SCR

52-week high / low

₹7,198 / ₹5,560

SCR

Market capitalisation

₹17,256 crore (about US$1.97 billion at end-August 2026 per PitchBook)

SCR

Trailing P/E

21.7x

SCR

Price to book

2.77x (book value ₹2,113 per share)

SCR

Dividend yield

0.51%

SCR

Enterprise value

About ₹15,700 crore (market capitalisation less ₹1,578 crore of net treasury funds at March 2026; derived)

Derived

EV / trailing sales

About 2.4x on ₹6,643 crore

Derived

EV / trailing operating profit

About 13.2x on ₹1,189 crore, before other income

Derived

Forward P/E

20.76x

StockAnalysis

Share Price & Returns

PeriodReturn

1 year

About minus 3% to minus 5% (ScanX minus 3.27%; SCR minus 5%)

3 years

Minus 6% per year compounded (SCR)

5 years

Minus 10% per year compounded (SCR); minus 38.06% cumulative (ScanX)

10 years

Plus 9% per year compounded (SCR)

Source Details

SourceDateView

HDFC Sky (HDFC Securities retail research)

August 2026

Buy in the ₹6,765–6,840 band; targets ₹7,341 and ₹7,784

Unnamed broker via ScanX

9 January 2026

Buy; target ₹8,500

Motilal Oswal via Trendlyne

FY2026 notes

—

Trendlyne consensus

—

Average target ₹7,725 from four brokers

Elara Capital via ScanX

4 May 2026

Accumulate; target price as printed not reliable

Income Statement and Margin Analysis (%) (Annual)

MetricFY2027EFY2028E

Revenue (INR Cr)

6,7967,496

EBITDA (INR Cr)

1,1941,336

EBITDA margin (%)

17.617.8

Net profit (INR Cr)

757883

EPS (INR)

257.1299.6

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

2532.5202530

Payout ratio (%)

1219181513

Credit Ratings

AgencyRatingOutlookDate

CARE Ratings (long-term bank facilities)

CARE AA+

Stable

Reaffirmed 1 October 2025

CARE Ratings (short-term bank facilities)

CARE A1+

—

Reaffirmed 1 October 2025

Moody's, S&P, Fitch

Not rated

——

Analyst Conclusions

Management guidance. Atul gives no numeric guidance. The qualitative message from April 2026 is to grow from capacity already built (₹1,700 crore of unrealised sales), keep capex low, measure performance by free cash flow, and embed digital tools. The only new capital commitment since is the ₹167 crore phenoxy herbicide project.

Consensus expectations. The one detailed estimate set retrieved projects revenue of ₹6,796 crore and EPS of ₹257 for FY2027 and ₹7,496 crore and ₹300 for FY2028 (HDFC Sky). After a first quarter that delivered ₹83 of EPS, upgrades are likely if margins hold.

Bull case

  1. Operating leverage is arriving. Q1 FY2027 operating margin was 21% against 16–17% through FY2026, and the POC segment result rose 140% year on year. If POC sustains even a mid-teens EBIT margin on a ₹5,000 crore revenue base, group EBIT would rise by several hundred crore without new capital.

  2. Growth is pre-funded. ₹1,700 crore of unrealised sales represents 27% volume headroom; capex was ₹175 crore in FY2026 against operating cash flow of ₹1,023 crore.

  3. Balance sheet optionality. ₹1,578 crore of net treasury funds, about 9% of market capitalisation, can fund acquisitions in crop protection retail, further downstream integration, or a larger capital return.

Bear case

  1. Earnings quality. FY2026 PAT growth of 38% was helped by a doubling of other income and a ₹47 crore tax refund; Q1 FY2027 benefited from pricing and inventory gains. Stripping these out, underlying growth is closer to revenue growth.

  2. Structural returns. POC absorbs 73% of segment capital at a 14% RoCE, and the businesses where Atul added capacity (liquid epoxy, caustic soda) are those most exposed to Chinese supply. Group ROE has not exceeded 12% since FY2022.

  3. Capital discipline. Cash is accumulating in treasury funds that earn less than the cost of equity, the payout ratio is only 13%, and the stated interest in acquisitions introduces execution risk for a company with little M&A history.

Catalysts and monitorables for the next 12 months

Analyst verdict. Atul enters the second half of FY2027 in its strongest financial position in seventy-nine years. Revenue is at a record, operating cash flow has crossed ₹1,000 crore, the heavy capex cycle is finished, and the balance sheet holds more than ₹1,500 crore of surplus funds. The latest quarter showed, for the first time since the 2021 peak, what the enlarged asset base can earn when prices cooperate.

Yet the evidence does not support treating Atul as a high-quality specialty compounder. Half its operating profit comes from a Life Science segment that is excellent but growing in single digits. The other half comes from a Performance segment that consumed most of the new capital and still earns returns close to the cost of capital. R&D at under 1% of revenue will not change that mix quickly, and the company's own slides show how wide the scale gap with China has become. The market's verdict, a share price lower than five years ago, is harsh but not irrational.

The balance of probabilities for the next year is nevertheless favourable. Volume headroom is real and quantified, depreciation has plateaued, interest cost is negligible, and each incremental rupee of contribution falls largely to profit. If operating margin settles at 18–19% rather than reverting to 16%, earnings per share near ₹300 are achievable a year ahead of published estimates, which would put the stock below 20 times earnings with a tenth of its value in cash.

The decisive variable is management's use of that cash. A disciplined acquisition that gives the retail brands scale, or a materially higher payout, would address the returns problem directly. Continued accumulation would not. Atul is a sound, conservatively run franchise with cyclical upside; whether it becomes more than that depends on capital allocation decisions that have yet to be made.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAge / year of birth

Sunil Siddharth Lalbhai

Chairman and Managing Director; promoter

MD since June 1984; Chairman since August 2007

MS in Chemistry (University of Massachusetts) and MS in Economic Policy and Planning (Northeastern University); also Chairman of Amal Ltd; has held directorships at Britannia Industries, Navin Fluorine International, Bombay Dyeing and Pfizer Ltd at various times

Born 15 March 1960

Samveg Arvindbhai Lalbhai

Managing Director; promoter

Director since January 2000; MD since December 2001; reappointed for five years from 15 December 2026

Promoter family; directorships have included Bengal Tea and Fabrics and The Anup Engineering

Born 1961 (YF)

Gopi Kannan Thirukonda

Chief Financial Officer and Whole-time Director

CFO since July 2013; Director since October 2014

—

Born 1959 (YF)

Vivek Gadre

Whole-time Director

Board member since January 2025

—

Born 1962 (YF)

Dr Anuj Mittal

President – Research

Since 23 February 2026

About 30 years in R&D, process innovation and commercialisation; doctorate in organic chemistry

—

Lalit Patni

Company Secretary and Chief Compliance Officer

Compliance officer since October 2014 (MS)

——

“—” = not publicly disclosed.

Directors' Remuneration

NameTotal pay (INR Mn)

Sunil Lalbhai

134.5

Samveg Lalbhai

33.92

Gopi Kannan Thirukonda

25.81

Vivek Gadre

24.54

Board of Directors

NameRoleOn Board sinceNotes

Pradeep Banerjee

Independent Director

May 2022

Member, Risk Management Committee

Rangaswamy Iyer

Independent Director

1 May 2023 (five-year term)

Approved at AGM of 28 July 2023

Sujal Shah

Independent Director

October 2023

—

Sharadchandra Abhyankar

Independent Director

October 2023

Chairperson, Stakeholders Relationship Committee

Praveen Kadle

Independent Director

May 2024

—

Padmaja Chunduru

Independent Director

January 2025

—

Vinayak Deshpande

Independent Director

August 2026

IIT Kharagpur chemical engineer with about four decades in automation, infrastructure and EPC; DIN 00036827; five-year term approved by postal ballot, result 7 September 2026

Shareholding Trend

Holder categoryJun 2025Sep 2025Dec 2025Mar 2026Jun 2026

Promoters (%)

45.1845.2145.2245.2245.33

Foreign institutional investors (%)

8.778.317.457.507.44

Domestic institutional investors (%)

24.9724.9525.4125.8925.93

Public and others (%)

21.0521.5121.9221.3721.30

Number of shareholders

55,50556,95157,26356,85556,570

Competitive Landscape

Competitors by Segment

Sub-segmentPrincipal competitors (named)Atul's relative position

Crop Protection – Bulk Actives

UPL, PI Industries, Meghmani Organics, Bharat Rasayan, Nufarm (2,4-D), Chinese phenoxy producers

13% global share in 2,4-D and 14% in indoxacarb; mid-sized overall

Crop Protection – Retail

UPL, Rallis India, Dhanuka Agritech, PI Industries, Bayer CropScience, Sumitomo Chemical India

Small (₹278 crore) but with category-leading brands

Pharmaceuticals

Aarti Pharmalabs, Divi's Laboratories, Hikal, Paushak (phosgene), Chinese intermediates makers

Niche: global significance in dapsone only

Aromatics

Chinese p-cresol producers, Lanxess, Vinati Organics (adjacent chemistries)

Significant global share in p-cresol chain

Bulk Chemicals and Intermediates

Gujarat Alkalies and Chemicals, DCM Shriram, Grasim Industries, Meghmani Finechem (Epigral), Sumitomo Chemical (resorcinol)

Regional in chlor-alkali; nationally significant in resorcinol

Colors

Bodal Chemicals, Kiri Industries, Jay Chemical, Archroma, DyStar, Sudarshan Chemical (pigments)

Leader in vat dyes; minor in reactive dyes and pigments

Polymers – Performance Materials

Grasim (epoxy), Hindusthan Speciality Chemicals, Westlake Epoxy, Olin, Huntsman, Kukdo Chemical, Nan Ya Plastics

Among the top domestic epoxy producers

Polymers – Retail

Pidilite Industries, Astral (Resinova), Jubilant Agri and Consumer Products

Challenger: Lapox 7%, Polygrip 6%

Peer Comparison FY2026

MetricAtulAarti IndustriesDeepak NitriteSRF

Revenue (INR Cr)

5,5837,2718,28214,693

Revenue growth YoY (%)

1814812

EBITDA margin (%)

18141319

Net profit (INR Cr)

4993316971,251

R&D intensity (%)

0.7———

Company Snapshot

$526.54M

Revenue

3,139

Employees

1947

Founded

Gujarat, India

Headquarters

SWOT Analysis

Strengths

  • Net-cash balance sheet: treasury funds net of borrowings of ₹1,578 crore at March 2026, up from ₹691 crore a year earlier (AM26).
  • Record cash generation: operating cash flow of ₹1,023 crore and free cash flow of about ₹851 crore in FY2026 (AM26; SCR).
  • High-return Life Science segment: 23% EBIT margin and 39% RoCE on ₹1,074 crore of capital (AM26).
  • Quantified global positions: 13% of world 2,4-D and 14% of world indoxacarb (AM26).
  • Diversification: about 4,000 customers, 32 industries, 88 countries, and no disclosed customer concentration (AM26).
  • Credit quality: CARE AA+; Stable held continuously since at least August 2021 and reaffirmed on 1 October 2025 (CARE).
  • Regulatory standing: Ambernath API site cleared a USFDA inspection with zero observations in May 2024 (ANI).

Weaknesses

  • Low-return core: POC earns a 9% EBIT margin and 14% RoCE on ₹2,936 crore, 73% of segment capital (AM26).
  • Depressed group returns: three-year average ROE of 9.2% and FY2026 ROE of 11.5% against a ten-year average of 13% (SCR).
  • Margin erosion: operating margin of 16.5% in FY2026 against 25% in FY2021 (SCR).
  • Thin R&D: ₹41 crore, about 0.7% of revenue, in FY2025 (IAR25).
  • Reliance on non-operating income: other income of ₹203 crore was 23% of FY2026 PBT and included a ₹47 crore tax refund (AM26).
  • Sub-scale brands: Crop Protection – Retail at ₹278 crore and adhesive brand shares of 6–7% (AM26).
  • Combined Chairman and Managing Director role held by a promoter since 2007 (WEB).

Opportunities

  • Latent capacity: ₹1,700 crore of unrealised sales, equal to 27% of FY2026 revenue, requiring little capex (AM26).
  • Import substitution: India's €30 billion net chemical import position (AM26, citing VCI).
  • Competitor exits: two phosgene chemical producers in North America and Europe are expected to leave the business (AM26).
  • Downstream integration: MCPP-p and MCPA from in-house o-cresol and MCA (July 2026 board approval).
  • Wind and composites: Indian composites market growing 10–11% and wind-blade share targeted (AM26).
  • Inorganic growth: ₹1,578 crore of deployable funds and a stated intent to explore acquisitions in crop protection retail (AM26).
  • Pharma pipeline: 18 DMFs filed over FY2025–FY2026 and ₹110 crore of unrealised sales at Atul Bioscience (AM26).

Threats

  • Chinese scale: 46% of world chemical output and €127 billion of annual capex against India's €7.7 billion (AM26).
  • Export fragility: sales outside India fell 21% in FY2024 and have regained only part of the loss (MS).
  • Trade policy: US export headwinds flagged by brokers in January 2026 (ScanX); EU epoxy anti-dumping action in July 2025.
  • Pricing cyclicality: standalone realisations fell about 19% in a single year in FY2024 (IAR24).
  • Environmental and site concentration: Scope 1 and 2 emissions of 608,550 tCO2e and water withdrawal of 14.4 million kL, largely at one riverside complex (BRSR26).
  • Share price underperformance: five-year price CAGR of minus 10% and a fall in shareholder count from 67,753 (June 2024) to 56,570 (June 2026) (SCR).
  • Earnings quality in the latest quarter: Q1 FY2027 margin benefited from pricing and inventory gains (HDFC Sky), which may reverse.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Late April 2025FY2025 results: revenue ₹5,583 crore (+18%), PAT ₹499 crore (+54%); dividend of ₹25 per share proposed; new secretarial auditors appointedConfirms recovery from the FY2024 trough
May 2025Analyst meet: management cites more than ₹2,500 crore of unrealised sales potentialFrames the volume-led growth thesis
20 June 2025DPD Ltd, UK Phase-2 expansion inaugurated by Baroness Nicholson of Winterbourne and a Fujairah finance officialCapacity for date palm tissue culture
18 July 2025Q1 FY2026: revenue ₹1,478 crore (+11.8%); PAT attributable ₹127.77 crore (+14.2%); shares fell 4.31% to ₹6,972.10 on the BSEMarket disappointed by margin; raw material cost up 13.6%
25 July 202548th AGM heldDividend approved
29 July 2025Reports that the EU imposed anti-dumping duties on epoxy resins, flagged as potentially affecting Atul–
12 September 2025CARE reaffirms Amal Ltd at CARE A+; Stable; Amal debt-free at March 2025Associate credit strength
1 October 2025CARE reaffirms Atul at CARE AA+; Stable and CARE A1+Rating stability
17 October 2025Q2 FY2026: consolidated revenue ₹1,551.85 crore (+11.4%); PAT ₹182.37 crore (+30.7%). One aggregator lists the announcement date as 24 October 2025 and another as 16 October; the board meeting date reported by ScanX is 17 OctoberStrongest quarter of the year to that point
26 December 2025Intimation of board meeting for Q3 resultsRoutine
9 January 2026A broker maintains Buy with ₹8,500 target "despite US export headwinds"Tariff exposure acknowledged by the sell-side
23 January 2026Q3 FY2026: revenue ₹1,573.62 crore; PAT ₹163.54 croreProfit up about 47% year on year at the attributable level
23 February 2026Dr Anuj Mittal appointed President – Research; Dr Uday Bapat retiresR&D leadership transition
27 March 2026Intimation of 24 April board meetingRoutine
FY2026 (during year)Income tax refund of ₹47 crore from old assessments; ₹15 crore interest assistance received by a subsidiaryNon-recurring boosts to profit
FY2026 (during year)Atul Bioscience files 11 DMFs; both ABL units now USFDA inspectedRegulatory pipeline
FY2026 (during year)Valsad Raktadaan Kendra, supported by Atul Foundation, receives Gujarat Healthcare Excellence Award 2026Community standing
24 April 2026FY2026 results: revenue ₹6,273.54 crore (+12.4%); PAT ₹689.39 crore (+38.2%); Q4 PAT ₹211.12 crore (+62%); dividend ₹30 proposed; Samveg Lalbhai reappointed MDRecord revenue and cash flow
30 April 2026Analyst Meet 2026Five mandates; ₹1,700 crore of unrealised sales
4 May 2026Elara Capital reported to rate the stock Accumulate after Q4The target price printed in the headline retrieved (₹27,305) is implausible against a share price near ₹6,000 and is not relied on
13 May 2026Launch of Mylonis, Salix Gold and TikadisProprietary retail products for rice, soybean and groundnut
4 June 2026Disclosure of pledged shares equal to 0.44% of capitalSmall; monitor
7 July 2026Integrated Annual Report 2025-26 dispatched; BRSR filed showing Scope 1 and 2 emissions of 608,550 tCO2e, down from 787,623ESG disclosure
17 July 2026Record date for dividend; book closure 18–24 JulyCorporate action
24 July 2026Q1 FY2027: revenue ₹1,847.95 crore (+25%); PBT ₹346.83 crore (+96%); PAT ₹253.93 crore (+92%); POC segment result ₹239.83 crore versus ₹100.00 croreStep change in POC profitability
24 July 2026Board approves ₹167 crore MCPP-p and MCPA projectFirst sizeable new capex since the FY2022–FY2024 cycle
31 July 202649th AGMDividend and MD reappointment on agenda
5 August 2026AGM speech, presentation and video uploadedDisclosure
6 August 2026Postal ballot notice for appointment of Vinayak Deshpande as Independent DirectorBoard refresh
7 September 2026Postal ballot result: appointment approved with requisite majorityGovernance
28 September 2026Board meeting fixed for 23 October 2026 for Q2 FY2027 results; trading window closed 1–25 OctoberNext catalyst

Product Offering

  • Atul Ltd.
    • Bisphenol A-based unmodified liquid resin
    • Bisphenol A-based modified liquid resin
    • Bisphenol A-based solid resin
    • Bisphenol F-based resin
    • Bisphenol A/F-based resin
    • Solvent cut resin
    • Cycloaliphatic resin
    • Epoxy phenol novolac resins
    • Organic Pigments

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 50,810 Mn in FY2022 to INR 62,740 Mn in FY2026.
Atul Ltd. — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations50,81054,28047,26055,83062,740

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.